

## MONOCLONAL ANTIBODY TO MOUSE TNF-ALPHA

### Clone V1q



---

|                              |  |
|------------------------------|--|
| <b>Catalog nr</b>            | HM1021 (lot number and expiry date are indicated on the label)   |
| <b>Description</b>           | Tumor Necrosis Factor alpha (TNF-alpha) is a cytokine which has various immunomodulatory, anti-tumor and toxic effects. TNF-alpha has been detected in various inflammatory status and appears to be a critical mediator in the lethality of septic shock. Furthermore, TNF-alpha has also been found in inflammatory foci such as synovial effusions in rheumatoid arthritis, systemic circulation in septic shock, parasitemia and rejection of renal transplants. The monoclonal antibody V1q reacts with both natural and recombinant TNF-alpha and shows neutralizing activity. |
| <b>Species</b>               | Rat IgD  |
| <b>Formulation</b>           | 1 ml (100 µg/ml) sterile 0.2 µm filtered antibody solution in PBS, containing 0.1% bovine serum albumin.   |
| <b>Application</b>           | The monoclonal antibody V1q can be used for inhibition of the biological activity. Furthermore the antibody V1q is useful for flow cytometry.  |
| <b>Use</b>                   | For flow cytometry dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:10. For inhibition of biological activity dilutions have to be made according to the amounts TNF-alpha to be inactivated.  |
| <b>Storage and stability</b> | Product should be stored at 4°C. Under recommended storage conditions, product is stable for one year.   |
| <b>Precautions</b>           | For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and Federal rules in the use of this product. Hbt is not responsible for any patent infringements that might result with the use of or derivation of this product.   |
| <b>References</b>            | <ol style="list-style-type: none"><li>1. Echtenacher, B et al; Requirements of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. <i>J Immunol</i> 1990, <i>145</i>: 3762</li><li>2. Obermeier, F et al; Interferon-gamma (IFN-gamma) and tumor necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. <i>Clin Exp Immunol</i> 1999, <i>116</i>: 238</li></ol>  |
| <b>Also available</b>        | HC1060                      Recombinant Mouse TNF-alpha (E.coli-derived), 5x10 <sup>4</sup> units<br>HM2010                      Monoclonal antibody against Human TNF-alpha, clone 52B83; cross-reactive with mouse TNF-alpha   |